Federal contractor · public award history
AMGEN INC.
Parent: AMGEN INC. Unique Entity Identifier (UEI)D92HARF1LKA9
- Awards we know about
- 1
- Typical size
- $26.41M
- Middle of their public awards
- Dollars on those awards
- $26.41M
Most of their awards we can see fall roughly between $26.41M and $26.41M.
SAM.gov registration
- Status
- Active
- Purpose of registration
- All awards (Z2)
- Registration expires
- Mar 19, 2027
- Activation date
- Mar 19, 2026
- Primary NAICS (SAM)
- Pharmaceutical Preparation Manufacturing325412
Other NAICS on file
Business types (SAM)
Registration fields from the official SAM.gov public entity extract (monthly bulk). Not a substitute for live SAM checks.
Continue contractor research
Use the verified identifiers and public award record to investigate documented incumbents, compare competitors, or identify possible teaming partners. This is a research starting point, not a capability or partner recommendation.
These official USAspending contract records do not rate capability or past performance and do not tell you whether to team or bid.
Awarding agencies
- Department of Health and Human Services (1)
Industries & product codes
Award history
- Department of Health and Human Services$26.41MSep 4, 2025Procurement Instrument Identifier (PIID)75A50119C00061Research and Development in Biotechnology (except Nanobiotechnology)541714R&D- Medical: Specialized Medical Services (Advanced Development)AN73Contract awardUSAspending ↗
THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF ROMIPLOSTIM FOR TREATMENT OF HEMATOPOIETIC SUBSYNDROME-ACUTE RADIATION SYNDROME (HS-ARS) AND CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA (CIT) AND A DRUG DELIVERY DEVICE FEASIBILITY PROJECT WITH AN OPTION TO
For research only. This is not legal advice, a past-performance review, or a recommendation to team or bid. Check USAspending and SAM.gov.